Shares of Nu Skin Enterprises Inc. (NYSE:NUS) were up 2% during mid-day trading on Friday . The company traded as high as $52.45 and last traded at $50.90, with a volume of 691,562 shares. The stock had previously closed at $49.91.

A number of analysts have issued reports on NUS shares. Zacks Investment Research raised Nu Skin Enterprises from a “strong sell” rating to a “buy” rating and set a $44.00 price objective on the stock in a research note on Thursday, April 14th. Jefferies Group reaffirmed a “hold” rating and issued a $41.00 price objective on shares of Nu Skin Enterprises in a research note on Friday, June 17th. Pivotal Research reaffirmed a “buy” rating and issued a $55.00 price objective (up previously from $40.00) on shares of Nu Skin Enterprises in a research note on Friday, April 29th. Stifel Nicolaus lifted their price objective on Nu Skin Enterprises from $30.00 to $34.00 and gave the stock a “sell” rating in a research note on Friday, April 29th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $45.00 price objective (up previously from $38.00) on shares of Nu Skin Enterprises in a research note on Tuesday, April 19th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $44.72.

The stock’s 50-day moving average price is $44.04 and its 200-day moving average price is $37.53. The firm has a market capitalization of $2.86 billion and a P/E ratio of 29.66.

Nu Skin Enterprises (NYSE:NUS) last released its earnings results on Thursday, April 28th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.05. The firm earned $471.80 million during the quarter, compared to analysts’ expectations of $465.08 million. The business’s revenue was down 11.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.60 EPS. On average, equities analysts expect that Nu Skin Enterprises Inc. will post $2.76 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in NUS. California State Teachers Retirement System increased its position in Nu Skin Enterprises by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 111,382 shares of the company’s stock valued at $4,220,000 after buying an additional 1,703 shares during the period. California Public Employees Retirement System increased its position in Nu Skin Enterprises by 10.7% in the fourth quarter. California Public Employees Retirement System now owns 158,400 shares of the company’s stock valued at $6,002,000 after buying an additional 15,300 shares during the period. Engineers Gate Manager LP increased its position in Nu Skin Enterprises by 427.7% in the fourth quarter. Engineers Gate Manager LP now owns 41,159 shares of the company’s stock valued at $1,560,000 after buying an additional 33,359 shares during the period. New York State Common Retirement Fund increased its position in Nu Skin Enterprises by 11.2% in the fourth quarter. New York State Common Retirement Fund now owns 241,115 shares of the company’s stock valued at $9,136,000 after buying an additional 24,212 shares during the period. Finally, Old Mutual Global Investors UK Ltd. purchased a new position in Nu Skin Enterprises during the fourth quarter valued at $1,116,000.

Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care system and ageLOC Tru Face Essence Ultra anti-aging skin care serum.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.